Boehringer Ingelheim Rcv competitive analysis

Explore patent oppositions filed by Boehringer Ingelheim Rcv against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 10, 2026
Patent NumberTitleApplicantOpposition Date
Carbon-Source Regulated Protein Production In A Recombinant Host CellLONZAJan 9, 2023
Anti-Dll3 AntibodyCHUGAI SEIYAKU KABUSHIKI KAISHAMar 22, 2022
Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of CancerLINDHOFERNov 16, 2021
Cancer Patient Selection For Administration Of Wnt Signaling Inhibitors Using Rnf43 Mutation StatusIRMDec 15, 2020
Anti-B7-H6 Antibody, Fusion Proteins, And Methods Of Using The SameTRUSTEES OF DARTMOUTH COLLEGEDec 20, 2019
Cytotoxicity-Inducing Therapeutic AgentCHUGAI SEIYAKU KABUSHIKI KAISHAJun 12, 2019
Anti-Dll3 AntibodyCHUGAI SEIYAKU KABUSHIKI KAISHAJan 2, 2019
Molecules And Methods For Modulating Low-Density-Lipoprotein Receptor-Related Protein 6 (Lrp6)NOVARTISSep 25, 2018
Molecules And Methods For Modulating Low-Density-Lipoprotein Receptor-Related Protein 6 (Lrp6)NOVARTISJul 27, 2016

Explore Boehringer Ingelheim Rcv's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 10, 2026
Patent NumberPublication DateTitleTotal Oppositions
Nov 5, 2025Real Time Monitoring Of Product Purification3

Latest PTAB cases involving Boehringer Ingelheim Rcv

Discover the latest PTAB cases involving Boehringer Ingelheim Rcv, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Boehringer Ingelheim Rcv with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 10, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BOEHRINGER INGELHEIM4524589
LONZA43 - -